QuikPath RAPID Self, QuikPath, Singapore

Why COVID-19?
Six months after the WHO declared COVID-19 a pandemic, countries around the world are still battling the disease along with the economic burden of lockdowns imposed to contain and control the spread of the disease. While pharma companies across the world race to find a cure for this disease and develop vaccines, the only immediate solution to allow economies to re-open safely is to scale-up screening and make it easily accessible for the masses. For this purpose, we have developed two products – QuikPath RAPID and QuikPath RAPID Self

QuikPath RAPID Self

Easy-to-use kit, suitable for self-screening by anyone, anywhere. Results based on colorimetric reading.

  • HSA Approved
  • Target Genes: Orf1ab and N
  • Internal control: rActin
  • ‍Limit of Detection: 10 viral copies / µL
  • Reaction time: 40 mins, 1 test / run
  • Sensitivity: > 95%
  • Instrumentation: Standard heating block
  • ‍Storage: -20° C
  • ‍Shelf Life: 6 Months

Quikpath Brochure.PDF